View clinical trials related to Early-Stage Breast Cancer.
Filter by:The adjuvant radiotherapy (RT) of the early-stage breast cancer patients as local treatment aims to eliminate the potential microscopic residual disease in the surgery bed or satellites in its neighborhood. Nowadays accelerated partial breast irradiation (APBI) is recommended for highly selected patients. This prospective randomized study compares the targeted external beam APBI with commonly used accelerated whole-breast irradiation (WBI) in terms of feasibility, safety, tolerance, and cosmetic effects. It is designed as non-inferiority trial and its aim is to increase the level of evidence for establishment of external beam APBI in indicated patients into daily clinical practice.
In this research study, investigators are testing if a dose-increasing strategy for abemaciclib will have less side effects and be better tolerated than the standard dosage of abemaciclib for participants with early-stage high-risk hormone receptor positive breast cancer. The names of the study drugs involved in this study are: - Abemaciclib (CDK4 and CDK6 inhibitor) - Tamoxifen (Selective estrogen receptor modulator) - Anastrozole/Letrozole (Non-steroidal aromatase inhibitors) - Exemestane (steroidal aromatase inhibitor) - LHRH (Gonadotropin-releasing hormone agonist, or Luteinizing hormone-releasing hormone agonist)
This is a 24-week exercise programme consisting of aerobic exercise and muscle strength training, 3 sessions per week. The first 9 sessions are supervised by physiotherapists in person, followed by 63 sessions monitored remotely (video) or supervised by trainers at ActiveSG (Sport Singapore) gyms.
The COGNITION diagnostic platform elucidates the biomarker profile of neoadjuvant chemotherapy-resistant residual bulk tumors in high risk early breast cancer patients. The major goal is to provide a framework for genomic profiling, which serves as infrastructure for systematic biomarker-screening and -stratification for concise therapy-arm allocation in the interventional clinical phase II trial COGNITION-GUIDE (NCT05332561). In patients, who display a poor response to standard-of-care neoadjuvant chemotherapy, tissue samples before and after neoadjuvant therapy are subjected together with blood samples to comprehensive genomic profiling to identify patients potentially benefiting from biomarker-guided interventions in COGNITION-GUIDE. Samples not required for standard-of-care clinical procedures or genomic profiling are systematically collected in a dedicated bio-repository to fuel translational scientific companion programs. The continuously growing comprehensive database serves as an integrative resource for systematic, prospective multidimensional data collection (clinical records, biomaterial, genomic data). In summary, the overarching goal is to generate a precision oncology platform i) to identify clinically-actionable biomarkers and drug targets that drive genomics-guided therapies and ii) to couple the observational, diagnostic registry platform to the independent, biomarker-stratified clinical therapy trial COGNITION-GUIDE.
This is a prospective, single center, single-arm, phase IV study， to evaluate the effect of Huaier Granule on reducing the level of tumor markers in early-stage breast cancer patients.
Research background: Neratinib is an irreversible pan HER tyrosine kinase inhibitor, which belongs to one of tyrosine kinase inhibitors (TKI). In the non pCR HER2 positive breast cancer patients after neoadjuvant therapy, there is no study on macromolecular anti HER2 drugs combined with TKI drugs to treat HER2 positive breast cancer patients after neoadjuvant therapy. In addition, there is no prospective randomized controlled study results of trastuzumab combined with patuzumab versus trastuzumab combined with TKI drugs for HER2 positive breast cancer patients with RCBI-II after new adjuvant treatment. To sum up, this study is intended to design and evaluate the efficacy and safety of trastuzumab combined with nelatinib in the treatment of hormone receptor positive HER2 positive breast cancer RCBI-II patients after the new adjuvant treatment of trastuzumab combined with patouzumab. Objective: This study was designed to evaluate the efficacy and safety of trestuzumab combined with nelatinib in the adjuvant treatment of breast cancer patients with hormone receptor positive HER2 positive RCB I-II after the neoadjuvant treatment of trestuzumab combined with partuzumab. Trial design: Single center, randomized controlled phase III clinical study. Study content: Study content: The qualified subjects will be randomly (1:1) treated with the following scheme: Treatment plan: Experimental group: Trastuzumab combined with nelatinib Control group: Trastuzumab combined with Parstuzumab Nilatinib: Take 240 mg (6 tablets) orally once a day, which can be taken with food every 21 days as a cycle. After surgery, it starts to be used together with trastuzumab, and stops the next cycle when trastuzumab treatment is completed. Trastuzumab: loading dose 8mg/kg, maintenance dose 6mg/kg, intravenous infusion, once every three weeks, with a total of 18 cycles during the new adjuvant treatment. Patuzumab: loading dose 840mg/kg, maintenance dose 420mg, intravenous infusion, once every three weeks, with a total of 18 cycles during the new adjuvant treatment. Observation index: main index: Invasive disease free survival (IDFS) refers to the time from randomization to the first occurrence of local or distant disease recurrence or death. Secondary indicators: 1. Disease free survival (DFS): refers to the time from randomization to disease recurrence or death due to disease progression. 2. Overall survival (OS): the time from randomization to death from any cause. 3. Distant disease free survival (DDFS): the time when no metastatic lesion was found in other places except the primary lesion after treatment. 4. Incidence and severity of adverse events
The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.
The study is being done to research if hydroxychloroquine can prevent chemotherapy induced peripheral neuropathy. Certain chemotherapy drugs, like paclitaxel, are known to cause neuropathy which can impact quality of life. Currently, there are no options for preventing peripheral neuropathy. In addition, there are no useful methods to assess peripheral nerve damage. This study will also explore using a study MRI of patients' feet prior to starting chemotherapy and after they have completed chemotherapy to see if there is any difference in their nerve structure.
The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.